Wednesday, March 11, 2009

StemEx, a Gamida Cell-TEVA Joint Venture Cell Therapy Product, Receives Orphan Medicinal Product Designation in the European Union

Mar 11, 2009 - The Gamida Cell-Teva Joint Venture announced today that orphan designation was granted by the European Commission for the investigational medicinal product StemEx for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.

The details can be read here.

No comments: